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Abstract
The monocyte chemoattractant protein-induced protein (MCPIP) family consists of 4 members (MCPIP1–4) encoded
by the ZC3h12A-D genes, which are located at different loci. The common features of MCPIP proteins are the zinc
finger domain, consisting of three cysteines and one histidine (CCCH), and the N-terminal domain of the PilT
protein (PilT-N-terminal domain (PIN domain)). All family members act as endonucleases controlling the half-life of
mRNA and microRNA (miRNA). The best-studied member of this family is MCPIP1 (also known as Regnase-1).
In this review, we discuss the current knowledge on the role of MCPIP1 in cancer-related processes. Because the
characteristics of MCPIP1 as a fundamental negative regulator of immune processes have been comprehensively
described in numerous studies, we focus on the function of MCPIP1 in modulating apoptosis, angiogenesis and
metastasis.
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Background
The MCPIP family consists of four proteins (MCPIP1–4)
encoded by four genes (Zc3h12a-d in mice and ZC3H12A-
D in humans). MCPIP family members are multidomain
proteins; however, two of the domains—the zinc finger
domain and the PIN domain—determine their function. A
total of 55 proteins that contain CCCH zinc finger do-
mains are found in humans [1]. Most CCCH zinc finger
proteins with known functions act as regulators of RNA
metabolic processes, including mRNA splicing, polyadeny-
lation, export, translation, and decay [2].
PIN domains are approximately 130 amino acids in
length, and proteins possessing this domain function as nu-
clease enzymes that cleave single-stranded RNA (ssRNA) in
a sequence-independent manner. The name “PIN domain”
derives from the presence of such a domain at the N-
terminus of an annotated type IV pili twitching motility
(PilT) protein (the PilT N-terminal domain, or PIN do-
main). Proteins with PIN domains are present in all king-
doms of life and act in a metal-dependent manner, usually
via Mg2+ or Mn2+ [3–6].
All MCPIP family members have been shown to possess
an active PIN domain and to be involved in inflammatory
processes, although MCPIP1 is the most well-studied and
well-described family member. In this review, we focus en-
tirely on the role played by MCPIP1 in tumour-associated
processes. The central part of this review is intended to
summarize our current understanding about the role of
MCPIP1 in cancer development and progression. Recent
advances in elucidating the molecular mechanism of
MCPIP1 action have shed new light on its fundamental
immunomodulatory function. Importantly, negative regula-
tion of inflammatory reactions is already widely discussed;
thus, in this review, we concentrate on cancer-related pro-
cesses regulated by MCPIP1.
MCPIP1 participates in the degradation of transcripts
by recognizing specific stem-loop structures present in
their 3′ untranslated regions (UTRs) (Fig. 1). Our recent
studies showed that MCPIP1 recognizes a set of com-
mon target mRNAs encoding proteins that play import-
ant roles throughout the course of inflammation.
In addition to mediating direct endonucleolytic cleavage
of RNA molecules, MCPIP1 is also involved in protein
deubiquitination. By forming a complex with the TANK
and USP10 proteins, MCPIP1 plays an indirect role in the
deubiquitination of TRAF6. Via TANK-MCPIP1-USP10
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complex activity, ubiquitin residues are removed from
TRAF6 proteins by the USP10 deubiquitinase [7].
Main text
Mechanism of transcript degradation by MCPIP1
The level of mRNA in the cell results from competition
between mRNA degradation and translation initiation.
Mammalian cells contain two machineries by which RNA
molecules are degraded: P-bodies (PBs) and stress gran-
ules (SGs). PBs and SGs can be clearly distinguished from
each other by specific protein or RNA markers; however,
they also share many proteins and mRNA species [8].
PBs are dynamic complexes whose assembly is dependent
on the pool of nontranslated mRNA [9–11]. PBs contain a
conserved core of proteins involved in mRNA decay and
translational repression, such as the decapping enzyme
complex, translational repressors and 5′ to 3′ exonucleases
(reviewed in [12, 13]). SGs, also called mRNA silencing foci,
were initially described in 1984 in tomato cell cultures as
reversible aggregates of ribonucleoprotein complexes con-
taining untranslated mRNA [14]. Later, similar structures
were described in mammalian cells [15]. SGs are formed
when global protein synthesis is inhibited in response to
many different types of stress, such as UV irradiation,
oxidative stress, and energy depletion. SGs are tightly asso-
ciated with components of the translation machinery.
There are three major classes of intracellular RNA-
degrading enzymes (ribonucleases or RNases): endonucle-
ases, which cut RNA internally; 5′ exonucleases, which
hydrolyse RNA from the 5′ end; and 3′ exonucleases, which
degrade RNA from the 3′ end. Most RNases exhibit over-
lapping activities that result in redundancy of RNA degrad-
ation systems. Thus, multiple enzymes can recognize the
same target RNAs (reviewed in [16]). RNases recognize cis-
regulatory elements (CREs) in mRNA, such as secondary
structures [17, 18] or sequence motifs present in the 3′
UTR including binding sites of RNA-binding proteins
(RBPs) [19, 20].
MCPIP1 degrades transcripts in an adenine-uridine
element (ARE)-independent manner [21–23]. MCPIP1
physically interacts with stem-loop structures in the 3′
UTR of transcripts through its PIN domain, causing
mRNA destabilization followed by degradation [24]. High-
throughput sequencing of RNA isolated by crosslinking
immunoprecipitation (HITS-CLIP) revealed that the stem-
loop sequences preferably recognized by MCPIP1 contain
pyrimidine-purine-pyrimidine (YRY) loop motifs [24].
However, many transcripts identified experimentally, both
by our group and by other research teams, do not contain a
YRY motif. RNA immunoprecipitation assays and func-
tional assays on an MCPIP1 mutant with a mutated PIN
domain showed that these transcripts interact with
MCPIP1 and that their levels depend on the active form of
MCPIP1 (Fig. 1) [25].
In vitro analysis of recombinant MCPIP1 and oligonucle-
otides forming stem-loops from the 3′ UTR of IL-6 mRNA
showed that cleavage occurs at the loop site of the stem-
loop. Thus, the stem-loop structure is destabilized, and
ssRNA fragments are generated, which are further progres-
sively degraded through the following steps. MCPIP1
cleaves diverse sets of RNA stem-loop structures without a
specific sequence preference [25]. However, the mechanism
by which MCPIP1 recognizes its substrates in vivo remains
to be clarified. Interactors and/or posttranslational modifi-
cations of MCPIP1 may affect its substrate specificity. In
addition, size exclusion chromatography of the MCPIP1
and PIN proteins revealed that MCPIP1 undergoes homoo-
ligomerization during interaction with RNA substrates [25].
Fig. 1 MCPIP1 regulates number of processes directly. MCPIP1 physically interacts with stem-loop structures in the 3′ UTR of transcripts and
participates in their degradation. Destabilization of mRNA upon endonucleolytic cleavage by MCPIP1 leads to diminished protein translation and
influences on inflammation, adipogenesis, proliferation and apoptosis. MCPIP1 degrades also miRNA by cleaving the terminal loops of precursor
miRNAs and influences gene expression
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Importantly, MCPIP1 not only downregulates a set of
mRNAs but also acts as a suppressor of miRNA biogen-
esis by cleaving the terminal loops of precursor miRNAs,
thus counteracting Dicer1 activity [26]. Although MCPIP1
degrades miRNA and mRNA through the same mechan-
ism by recognizing specific structures in both types of
RNA targets, whether this protein is present in PBs, SGs
or both structures depending on circumstances is unclear.
The role of MCPIP1 in apoptosis
The role of MCPIP1 in the regulation of cell death was ori-
ginally demonstrated in human embryonic kidney (HEK)
293 cells and cardiomyocytes (Tables 1 and 2). Despite ac-
cumulating evidence supporting the proapoptotic role of
MCPIP1, knowledge of the means by which it induces cell
death is still very limited. Moreover, MCPIP1 may regulate
the apoptotic process both directly and indirectly [39]. The
indirect effect of MCPIP1 on apoptosis is connected to its
influence on the formation of SGs [40]. Expression of
MCPIP1 completely blocked SG formation and promoted
macrophage apoptosis under stress conditions, including
arsenite-induced oxidative stress, heat shock, and energy
deprivation [40]. Consistent with these findings, MCPIP1-
deficient cells (splenocytes and murine embryonic fibro-
blasts) spontaneously formed SG aggregates even in the
absence of stress and displayed apoptosis resistance. In
addition, elevated levels of MCPIP1 were detected in is-
chaemic human hearts—in situ hybridization showed the
presence of MCPIP1 transcripts, and immunohistochemis-
try demonstrated that the MCPIP1 protein colocalized
with apoptotic nuclei [39].
These findings are consistent with experiments per-
formed in Caki-1 cells as a model of clear cell renal cell
carcinoma (ccRCC). Overexpression of MCPIP1 reduced
cell viability, induced nuclear morphology characteristic
of late apoptosis and enhanced caspase 3/7 activity [33].
The proapoptotic properties of MCPIP1 are also trig-
gered by its involvement in pre-miRNA degradation
(Table 3). Boratyn and coworkers showed that overexpres-
sion of MCPIP1 in the BE(2)-C human neuroblastoma cell
Table 1 Effect of MCPIP1 on gene expression. Regulation of genes expression and proteins level by MCPIP1 was tested both in cells
with ZC3H12A overexpression or silencing. Cited results were obtained from studies using cells cultured in control conditions. We
did not include data obtained upon induction of differentiation (i.e. adipogenesis), nor stimulation (i.e. cytokines, LPS)
MCPIP1 OVEREXPRESSION
gene expression Experimental model Reference
HIF-1α, VEGF1, cdh12, cdh19, VE-cadherina HUVECs Niu et al., 2008 [27]
Ephrin-A1, IL-1β, Notch Homolog 4, Ephrin B2, PDGF α, TIMP-2,
Ephrin A3, Midkine, Thrombospondin 1, CSF-3b
Flt-1, Flk-1, Tie-2, CD31, Beclin-1a bone marrow mononuclear cells Niu et al., 2013 [28]
VEGF, COX2, SIRT-1a HUVECs Roy et al., 2013 [29]
Fas, Dedd2a MDA-MB-231 Lu et al., 2016 [30]
MBLN2, SLC3A2, DFFB, APAF1a BE(2)-C human neuroblastoma cell line Boratyn et al., 2016 [31]
CDKN1Aa, c ccRCC cell line Caki-1 Lichawska-Cieslar et al., 2018 [32]
gene expression Experimental model Reference
CD14, CD11ba bone marrow mononuclear cells Niu et al., 2013 [28]
TSP-1 and VEGI, p65 HUVECs Roy et al., 2013 [29]
Bcl2L1, Bcl2A1, Birc3, RelB, and Bcl3a MDA-MB-231 Lu et al., 2016 [30]
CTXN1, CNIH2, MCM10, CD248, RBM12, PAXIP1, SEPT3a BE(2)-C human neuroblastoma cell line Boratyn et al., 2016 [31]
SLC44A1, SLC29A4,
IL-6, VEGF, GLUT-1a ccRCC cell line Caki-1 Ligeza et al., 2017 [33]
c/EBPβ, SDF-1, Snail, Zeb2a ccRCC cell line Caki-1 Marona et al., 2017 [34]
HSPA5, AGR2, PLOD2, MMP2, NDRG1, NDRG2, SPHK1, ENPP2, ccRCC cell line Caki-1 Lichawska-Cieslar et al., 2018 [32]
NGEF, GPRC5B, TSC22D3, SGK2, FRAT1, RIPK4, DDB1 a, c
MCPIP1 SILENCING
gene expression Experimental model Reference
BCL2L1, BCL3, BIRC3, RELB, AND BCL2A1 MDA-MB-231 Lu et al., 2016 [30]
IL-8, VEGF, IL-6, c/EBPβ, SDF-1, CXCR4, Snail, Zeb2a ccRCC cell line Caki-1 Marona et al., 2017 [34]
aReal-time PCR analysis
bGene array analysis; expression profile of angiogenesis-related genes in GFP/hMCPIP-over GFP-infected HUVECs with fold induction > 5
cRNA-Seq analysis
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line resulted in a significant reduction in miR-3613-3p
levels [31]. Further investigation indicated that in those
cells, miRNA-3613-3p overexpression negatively regulated
the expression of apoptotic protease activating factor 1
(APAF1) [41]. Overexpression of wild-type but not mu-
tated MCPIP1 (with deletion of the PIN domain) in BE(2)-
C cells resulted in miR-3613-3p downregulation and
significant increases in pro-apoptotic DFFB and APAF1 at
the mRNA and protein levels [31]. Thus, in several cancer
cells characterized by low levels of MCPIP1, upregulated
miR-3613-3p may decrease the possibility of apoptosis
activation, whereas BE(2)-C cells overexpressing miR-
3613-3p exhibit inhibition of caspase-9 proteolysis [41].
On the other hand, a study by Oh and coworkers showed
an antiapoptotic role of MCPIP1 mediated via regulation
of apoptosis-related death receptor 5 (DR5). DR5 is a cell
surface receptor produced endogenously by various im-
mune cells, such as T cells and is responsible for TNF-
related apoptosis. MCPIP1 decreases both the total cellular
and cell surface expression of DR5, primarily through
modulating DR5 autophagic/lysosomal degradation. Mech-
anistically, the authors implicated indirect MCPIP1 action,
Table 2 Effect of MCPIP1 on gene expression. Regulation of genes expression and proteins level by MCPIP1 was tested both in cells
with ZC3H12A overexpression or silencing. Cited results were obtained from studies using cells cultured in control conditions. We
did not include data obtained upon induction of differentiation (i.e. adipogenesis), nor stimulation (i.e. cytokines, LPS)
MCPIP1 OVEREXPRESSION
protein level Experimental model Reference
cdh12, cdh19, VE-cadherina HUVECs Niu et al., 2008 [27]
Flt-1, Flk-1, Tie-2, VEGF, Beclin-1a bone marrow mononuclear cells Niu et al., 2013 [28]
CD31, VE-cadherinb
HIF1α, SIRT-1a HUVECs Roy, 2013 [29]
Ras-related protein Rab-11B, Testinc, e mesenchymal stem cells Labedz-Maslowska et al., 2015 [35]
Endothelin, IP-10, TIPM-1, MMP-3, NOVa
Pro-Caspase-3a MDA-MB-231, 4 T1 cell line Lu et al., 2016 [30]
PARP1a 4 T1 Lu et al., 2016 [30]
DFFB, APAF1a BE(2)-C human neuroblastoma cell line Boratyn et al., 2016 [31]
E-cadherina ccRCC cell line Caki-1 Marona et al., 2017 [34]
p21a ccRCC cell line Caki-1 Lichawska-Cieslar et al., 2018 [32]
protein level Experimental model Reference
PAI-1, iNOSa HUVECs Qi et al., 2010 [36]
TSP-1, VEGI, p65a HUVECs Roy et al., 2013 [29]
CAAX prenyl protease 1 homolog, Calumeninc, f
KCa
mesenchymal stem cells Labedz-Maslowska et al., 2015 [35]
HIF1α, HIF2αa ccRCC cell line Caki-1 Ligeza et al., 2017 [33]
c-Met, Src, βcatenin, Vimentin, c/EBPβa ccRCC cell line Caki-1 Marona et al., 2017 [34]
p53, p21a human primary keratinocytes Bugara et al., 2017 [37]
MCPIP1 SILENCING
protein level Experimental model Reference
c-Met, Src, βcatenin, Vimentina c/EBPβa ccRCC cell line Caki-1 Marona et al., 2017 [34]
IL-8, VEGF, IL-6d
Cyclin D1a human primary keratinocytes Bugara et al., 2017 [37]
IL-8d
VCAM-1a HUVECs Li et al., 2018b [38]
protein level Experimental model reference
E-cadherina ccRCC cell line Caki-1 Marona et al., 2017 [34]
awestern blot analysis
bimmunofluorescence analysis
cproteomic analysis by mass spectroscopy
dELISA
efold change > 5
ffold change <−5
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showing the involvement of this protein in deubiquitina-
tion, which leads to decreased DR5 stability. In addition,
suppression of MCPIP1 by gene knockdown enhanced
TRAIL- or DR5-induced apoptosis in cancer cells, as mani-
fested by the activation of caspase 3 and 8 and subsequent
DNA fragmentation [42].
MCPIP1 also regulates apoptosis directly via a mechan-
ism directly linked to its enzymatic activity (Tables 1 and 2)
[30]. Studies in the breast cancer cell line MDA-MB-231
indicated that MCPIP1 functions as a potent tumour
suppressor that induces apoptosis by selectively enhancing
the decay of antiapoptotic gene mRNA transcripts. Lu and
coworkers identified 31 transcripts affected by MCPIP1
expression, of which 6 antiapoptotic genes were downregu-
lated and 25 proapoptotic genes were upregulated [30].
RNA immunoprecipitation experiments demonstrated that
MCPIP1 directly binds and cleaves mRNAs encoding
Bcl2L1, Bcl2A1, RelB, Birc3, and Bcl3. Finally, analysis of
human samples revealed that MCPIP1 expression is sup-
pressed in breast tumour cells, which, in turn, may help
these cells evade apoptosis [30].
The antiproliferative function of MCPIP1
Similar to resistance to cell death, sustained proliferative
signalling is another important hallmark of cancer.
MCPIP1 is primarily known as a negative regulator of
inflammation; however, it also regulates cell proliferation.
The first interesting observation came from a study
performed by Lu and coworkers, who demonstrated de-
creased MCPIP1 protein and RNA levels in breast cancer
specimens [30]. Additionally, MCPIP1 inhibited the prolif-
eration of breast cancer cells both in vitro and in vivo.
The authors proved that MCPIP1 suppressed the growth
of breast tumours in vivo by inhibiting cell proliferation
and concomitantly inducing apoptosis. Inoculation of
MDA-MB-231/Tet-On tumour cells into the mammary
glands of immunocompromised mice allowed the study of
tumour growth upon MCPIP1 overexpression. The day
after MCPIP1 induction with doxycycline in the tumour-
bearing mice, the tumours started to shrink and then
rapidly disappeared within 6 days, but the tumours in con-
trol mice continued to grow [30].
A low level of MCPIP1 is also a signature of ccRCC
[33]. MCPIP1 expression varies depending on the tumour
grade and decreases significantly with tumour progression,
which suggests that MCPIP1 is involved in cancer growth
and metastasis [34]. Studies performed in the ccRCC cell
lines Caki-1 (metastatic) and Caki-2 (primary tumour)
strongly support the antiproliferative function of MCPIP1
[32, 34]. MCPIP1 depletion in ccRCC cells significantly
enhanced tumour cell proliferation in both examined cell
lines, Caki-1 and Caki-2.
The antiproliferative action of MCPIP1 was also con-
firmed in animal studies. The growth of human ccRCC
was assessed in an in vivo xenotransplantation model
established in NOD-SCID mice via subcutaneous injec-
tion of Caki-1 cells. These experiments proved that in-
hibition of MCPIP1 in Caki-1 cells affected both tumour
growth and weight. The effect was opposite when cells
with MCPIP1 overexpression were used [34].
Moreover, data from human neuroblastoma biopsies
were even more unambiguous, since MCPIP1 transcrip-
tion was not detected in any sample from the 29 speci-
mens analysed by Skalniak and coworkers [43]. Similar to
primary tumours, human neuroblastoma cell lines exhib-
ited low protein levels of MCPIP1, and overexpression of
the ZC3H12A gene in BE(2)-C cells caused a significant
decrease in cell viability and proliferation [43].
One mechanism explaining the influence of MCPIP1
on the proliferation rate is the involvement of this RNase
with p21Cip1 (CDKN1A) mRNA. Caki-1 cells expressing
MCPIP1 showed significantly higher expression of
p21Cip1 protein and mRNA than control and D141N
cells (with a point mutation in MCPIP1 resulting in an
inactive catalytic site). The p21Cip1 protein belongs to
the Cip/Kip family of inhibitors and blocks the cell cycle
by inhibiting Cyclin-Cdk complexes. During S phase,
p21Cip1 degradation is regulated by the activity of the
Cul4-DDB1-Cdt2 E3 ligase. In our RNA-Seq analysis,
the transcript levels of damage-specific DNA binding
Table 3 Effect of MCPIP1 on miRNA expression. Selection of positively and negatively regulated miRNA by MCPIP1. Negative
regulation of miRNA by MCPIP1 was analyzed either by overexpression of ZC3H12A (more MCPIP1 protein leads to diminished
amount of miRNA), or ZC3H12A silencing (less MCPIP1 protein results in miRNA accumulation)
MCPIP1
miRNA Experimental model Reference
miR-155a Jurkat T cells Suzuki et al., 2011 [26]
miR-16a THP-1 Suzuki et al., 2011 [26]
miR-21, −26a, −107, − 182, −146a, −17-5p, −135b, let-7 ga HepG2, HEK293T Suzuki et al., 2011 [26]
miR-20b, miR-34ab HUVECs Roy et al., 2013 [29]
miR-3613-3pb BE(2)-C human neuroblastoma cell line Boratyn et al., 2016 [31]
asilencing of MCPIP1 increases miRNA level
boverexpression of MCPIP1 decreases miRNA level
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protein 1 (DDB1) were reduced in MCPIP1-expressing
cells compared with control cells or cells expressing
MCPIP1 with an inactive PIN domain (D141N). The
RNase activity of MCPIP1 is indispensable for the deg-
radation of DDB1 transcripts, which in turn may lead to
p21Cip1 accumulation. Thus, MCPIP1 inhibits the cell
cycle progression and growth of Caki-1 cells by upregu-
lating the cell cycle inhibitor p21Cip1 [32]. In addition,
siRNA silencing of MCPIP1 in human primary keratino-
cytes was shown to decrease the levels of phosphorylated
p53 and p21 proteins and to upregulate Cyclin D1 ex-
pression after exposure to UVB radiation stress, which
may serve as a mechanism of survival promotion in
MCPIP1-depleted cells [37].
Additionally, MCPIP1 controls the proliferation rate
and tumorigenesis by controlling the half-life of miR-
155 (Table 3) [26]. MCPIP1 was initially described to
modulate the immune response via the miR-155/c-Maf
axis [26]. In addition to acting as a regulator of the
immune response, miR-155 is thoroughly described as
an oncogenic miRNA (oncomiR) that contributes to the
development of leukaemia and breast, lung and stomach
tumours. MiR-155 was described to promote tumorigen-
esis by targeting several factors, thus enhancing prolifer-
ation, granting resistance to cell death (reviewed in [44])
and inducing angiogenesis [45]. As already discussed,
the expression of MCPIP1 was reported to be downregu-
lated in several carcinoma types, including breast cancer,
neuroblastoma, and ccRCC. Upregulation of miR-155 is
a potential MCPIP1-dependent effect contributing to the
promotion of tumorigenesis. The regulation of another
cancer-related miRNA, miR-146a, by MCPIP1 was inves-
tigated by several groups [26, 46, 47]. A study by Qu and
coauthors showed that MCPIP1 weakens the LPS induc-
tion of miR-146a in THP-1 cells treated with type I
interferon (IFN) [46]. The miR-146a targets include sev-
eral factors crucial for proinflammatory signalling (e.g.,
tumour necrosis factor receptor-associated factor 6
(TRAF6) and interleukin-1 receptor-associated kinase
(IRAK-1)) [48], and hence, miR-146a deficiency in the
white blood cells of systemic lupus erythematosus pa-
tients is correlated with upregulation of MCPIP1 expres-
sion and overactivation of inflammatory responses [46].
Thus, MCPIP1 regulates the expression of both miR-155
and miR-146a, which are important modulators of
immune processes and tumorigenesis. However, those
miRNAs usually exert opposing roles in the regulation
of the immune functions, and their expression is often
deregulated in tumours [48, 49].
The role of MCPIP1 in the regulation of angiogenesis
The formation of tumour-associated vasculature (i.e.,
tumour angiogenesis) has emerged as a critical step pro-
moting local tumour progression and metastatic spread.
Accumulating evidence indicates that MCPIP1 plays a
role during the process of angiogenesis in regulating in-
flammation, transcription factor activity, the production
of angiogenic factors and miRNA biosynthesis. However,
studies in tumour cells indicate that MCPIP1 may
exhibit diverse actions under normal and pathological
conditions.
Inflammation is a major inducer of angiogenesis dur-
ing tumour progression [50], and inflammatory cyto-
kines have been reported to facilitate a broad spectrum
of tumour development processes. The proinflammatory
cytokines IL-1, IL-6 and monocyte chemotactic protein-
1 (MCP-1) are required for angiogenesis and tumour
growth and promote the invasion and metastasis of
cancer cells in animal models. The first studies of the
role of MCPIP1 in the process of angiogenesis showed
that the treatment of human umbilical vein endothelial
cells (HUVECs) with the inflammatory agents TNF-α, IL-
1β, IL-8 and MCP-1 increased expression of gene coding
for MCPIP1, which subsequently induced angiogenesis-
related properties and the expression of angiogenesis-
related genes, resulting in capillary-like tube formation
(Tables 1 and 2) [27, 51]. Moreover, forced MCPIP1 ex-
pression causes oxidative and nitrosative stress, resulting
in ER stress and ultimately leading to autophagy, which is
required for angiogenesis [51].
In addition, the influence of MCPIP1 on the acquisition
of angiogenic properties has been documented in different
types of cells (Tables 1 and 2). The Kollatukudy group
showed that MCPIP1 expression increased during MCP-1-
induced transdifferentiation in human bone marrow mono-
nuclear cells (BMNCs) [28]. MCPIP1 induced the acquisi-
tion of an endothelial cell-like morphology, downregulation
of the monocytic markers CD14 and CD11b, upregulation
of the endothelial markers Flk-1 and Tie-2, induction of
cdh-12 and -19 expression, activation of ER stress, and au-
tophagy [28]. These results demonstrate that MCPIP1 may
be an important regulator of inflammatory angiogenesis.
Angiogenesis regulation is also tightly connected with the
expression of adhesion molecules on the endothelial surface.
Overexpression of MCPIP1 has been described to suppress
VCAM-1 expression and monocyte adhesion to human
endothelial cells. Conversely, knockdown of MCPIP1 in-
creases cytokine-induced VCAM-1 expression in HUVECs
and enhances monocyte adhesion [36]. Moreover, studies by
the Fu group showed that increased MCPIP1 protein levels
in endothelial cells resulting from the inhibition of MALT1
protease activity suppress endothelial activation. Moreover,
correlations have been found between increased levels of
MCPIP1 and both inhibition of TNFα-induced VCAM-1
expression in HUVECs and LPS-induced VCAM-1 expres-
sion in mice. In addition, inhibition of MALT1 protease
activity significantly inhibits TNFα-induced adhesion of
THP-1 monocytic cells to HUVECs [38].
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MCPIP1 may play a key role in the vascularization
process by controlling the levels of proangiogenic tran-
scripts and proteins. Enhanced expression of MCPIP1
has been shown to increase the angiogenic capacity and
the expression of proangiogenic genes, such as those
encoding the intranuclear transcription factor Gata-2 and
membrane VE-cadherin. These two genes allow mesenchy-
mal stem cells (MSCs) to differentiate into endothelial cells.
Additionally, MCPIP1-overexpressing MSCs secrete in-
creased levels of endothelin, TIMP-1, Serpin E1, IFN-γ-
inducible protein-10 (IP-10), MMP-3, stromal cell-derived
factor 1 (SDF-1), osteopontin and insulin-like growth
factor-binding protein 9 (Tables 1 and 2) [35]. Moreover,
the Kollatukudy group [27] showed that transfection of
HUVECs with an MCPIP-GFP expression vector induced
HIF-1α and VEGF production, whereas silencing of
MCPIP1 by siRNA suppressed MCP-1-induced expression
of HIF-1α and VEGF. Angiogenesis gene array analysis
revealed that MCPIP induced the upregulation of 31 of 113
genes known to contribute to the augmented angiogenic
properties of endothelial cells (Tables 1 and 2) [27]. Further
studies showed that low levels of MCPIP1 in ccRCC induce
endothelial cell angiogenesis and that the lack of MCPIP1
RNase activity is responsible for the secretion of proangio-
genic factors—VEGF, IL-8 and IL-6—by tumour cells [34].
The effect of MCPIP1 on vascularization might be trig-
gered by the regulation of transcription factors such as
HIFs or NF-κB. Indeed, Caki-1 cells overexpressing
MCPIP1 exhibit diminished levels of HIF1α and HIF2α
under hypoxic conditions [33]. The mechanism under-
lying the diminished level of HIF2α is based on a decrease
in the half-life of the transcript coding for this protein.
Consequently, cells overexpressing MCPIP1 display de-
creased expression levels of transcripts coding for VEGFA
and IL-6 [33]. Inhibition of NF-κB activity by MCPIP1
leads to a reduction in the levels of NF-κB target genes,
including those encoding antiangiogenic factors such as
thrombospondin-1 (TSP-1) and VEGI, which are natural
inhibitors of angiogenesis [29].
A study by Roy and coworkers indicated that the anti-
Dicer RNase activity of MCPIP1 is also critical for
modulating angiogenesis. In HUVECs, the expression of
antiangiogenic miR-20b and miR-34a is MCPIP1-
dependent [29]. Overexpression of wild-type MCPIP1
but not the RNase-dead mutant decreased the levels of
miR-20b and miR-34a. Conversely, silencing of MCPIP1
upregulated miR-20b and miR-34a expression upon
stimulation with TNF-α or IL1-β. These miRNAs affect
the expression of HIF-1α and SIRT-1, which are the crit-
ical positive regulators of blood vessel formation. Specif-
ically, miR-20b represses HIF-1α and miR-34a affects
SIRT-1 translation. Roy and coworkers further showed
that in HUVECs, overexpression of MCPIP1 induces
tube formation, as described previously [27, 29]. This
effect is, however, inhibited when MCPIP1 is cotrans-
fected with either miR-20b or miR-34a mimetics, most
likely via downregulation of HIF-1α and SIRT1 [29].
In addition to directly regulating proangiogenic cyto-
kines, MCPIP1 can regulate angiogenesis indirectly. Over-
expression of VEGF has been reported to stimulate
angiogenesis by upregulating SDF-1, a chemotactic chemo-
kine, thereby recruiting CXCR4-positive proangiogenic
myeloid cells [52] and endothelial progenitor cells from the
bone marrow [53]. In addition, SDF-1 and VEGF synergis-
tically induce neoangiogenesis in tumours [54]. Studies in
Caki-1 cells showed that MCPIP1 silencing increases SDF-
1 expression both in vitro and in vivo and that the RNase
activity of MCPIP1 controls the level of SDF-1 mRNA
[34]. The CXCR4/SDF-1 axis can coordinate the metastasis
of various tumours, and our observations not only demon-
strate the impact of MCPIP1 on tumour angiogenesis but
also highlight the role of MCPIP1 downregulation in
potentiating SDF-1-CXCR4 signalling.
The current research shows that MCPIP1 can regulate
angiogenesis by different means in normal and tumour
cells. In normal endothelial cells, MCPIP1 induces
proangiogenic properties by stimulating the secretion of
chemokines and growth factors. On the other hand, tu-
mours are characterized by a low level of MCPIP1 and a
well-developed tumour vasculature. This low level of
MCPIP1 in tumour cells is correlated with a high level
of proangiogenic factors, which activate endothelial cells
to form blood vessels in progressing tumours (Fig. 2).
MCPIP1 regulates tumour metastasis
One of the most dangerous features of malignant tu-
mours, which are the most common cause of death in pa-
tients with diagnosed cancer, is the ability of tumour cells
to metastasize. The critical stage in the process of metas-
tasis is epithelial-to-mesenchymal transition (EMT), in
which epithelial cells acquire mesenchymal features that
facilitate their migration, invasion of neighbouring tissues
and metastasis. During EMT, polarized epithelial cells,
which have high expression levels of E-cadherin and other
proteins characteristic of the epithelial cell phenotype, are
influenced by growth factors, cytokines, and other envir-
onmental factors to undergo a change to an elongated
morphology and become migrating cells expressing pro-
teins such as vimentin, fibronectin, and N-cadherin, with
a concomitant decrease in E-cadherin expression [55].
An important role of MCPIP1 in mediating the meta-
static potential of cancer cell lines was shown in ccRCC
cell lines. The decrease in MCPIP1 expression was cor-
related with the presence of the mesenchymal pheno-
type, which is essential for the metastatic process, and
with a decrease in the E-cadherin level, an increase in
the vimentin and β-catenin levels and a consequent in-
crease in migration activity [34]. The reduction in the E-
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cadherin level was inversely correlated with the expres-
sion of the Snail and ZEB-2 transcription factors, which
suppress E-cadherin expression [56, 57]. Moreover, si-
lencing of MCPIP1 in ccRCC cells was associated with
both an increased number of circulating tumour cells in
mouse blood and augmented lung metastasis [34].
Similar results were obtained by Lu and colleagues,
who showed that the induction of MCPIP1 expression in
MDA-MB-231/Tet-On tumour cells inoculated into the
mammary glands of immunocompromised NSG mice
significantly reduced tumour growth and lung metasta-
sis. Moreover, MCPIP1 expression is inversely correlated
with survival in breast cancer patients [30].
Moreover, MCPIP1 affects the expression level and
phosphorylation of the c-Met (a mesenchymal-epithelial
transition factor) receptor (Fig. 2). c-Met is a receptor
tyrosine kinase that is expressed on the surface of various
epithelial cells. The gene coding for c-Met is considered a
protooncogene because abnormal activation of c-Met can
promote the development and progression of multiple
cancers, such as liver, lung, colon, breast, pancreatic, ovar-
ian, prostate, and gastric carcinomas, in addition to can-
cers of the nervous system, such as glioblastoma [58–60].
MCPIP1 overexpression has been shown to reduce the ex-
pression and endogenous phosphorylation levels of c-Met
and decrease the level of Src kinase in ccRCC [34]. The
gene coding for C-Met is a direct target of NFκB, and
MET participates in NFκB-mediated cell survival [61].
The regulation of NF-κB transcription factor activity by
MCPIP1 could thus be expected to influence the level and
function of the c-Met receptor but the regulation of the c-
Met mRNA level by MCPIP1 needs to be clarified.
In a recent study of cell migration at the single-cell level,
Zhuang and coauthors found that the expression of
MCPIP1 is related to the mobility of cancer cells [62]. In
particular, an inverse correlation between the migratory
potential of the MCF-7, MDA-MB-231 and SUM-159
breast cell lines and the mRNA/protein expression of
MCPIP1 was found. Transient transfection of MDA-MB-
231 cells with a vector encoding MCPIP1 reduced cell
mobility, and RNA-Seq of those cells revealed enrichment
of TGF-β-suppressed genes in MCPIP1-overexpressing
cells. The authors further showed that inhibiting TGF-β in
MDA-MB-231 cells with low levels of MCPIP1 expression
restored their migratory phenotype to that observed in the
corresponding cells with high levels of MCPIP1 expres-
sion. This mechanism was further validated in an in vivo
xenograft model, in which high MCPIP1 expression inhib-
ited tumour growth and inhibit breast cancer invasion,
while additional treatment of xenografts with low levels of
MCPIP1 expression with a TGF-β inhibitor attenuated
their growth phenotype. These results indicated that the
inhibitory effect on cell migration and metastasis of
MCPIP1 might be associated with the suppression of
TGF-β signaling pathway [62].
MCPIP1 also controls the EMT process by negatively
regulating the maturation of miRNA-200 family members,
as shown in pancreatic adenocarcinoma [63]. In several
pancreatic tumour cell lines, the MCPIP1/Dicer1 ratio and
the levels of miRNA-200 family members are inversely
correlated (Table 3). MiR-200 family members perform
tumour suppressor functions, and their expression is fre-
quently suppressed in cancer cells. These miRNAs regulate
EMT by targeting ZEB1 and ZEB2, transcriptional repres-
sors of E-cadherin. Decreased expression of miRNA-200
family members leads to upregulation of ZEB1/ZEB2
expression, promoting the mesenchymal-like state. This
observation contrasts with the previously thoroughly de-
scribed role of MCPIP1 in EMT regulation in renal carcin-
oma cells. However, the role of MCPIP1 in pancreatic
adenocarcinomas has not yet been investigated.
Considering the current knowledge, MCPIP1-mediated
control of the levels of transcription factors (NFκB and C/
EBPβ) and signalling proteins (JNK and Akt) may play a
Fig. 2 Mechanisms of indirect MCPIP1 action. MCPIP1 plays important role in affecting angiogenesis or metastasis and transcription
factors activity
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key role in the activation and regulation of the EMT
process [34, 62, 64].
Conclusions
The interactions between cis-acting elements within mRNAs
and trans-acting factors (RBPs) play a pivotal role in the
posttranscriptional control of gene expression [65, 66]. RNA
molecules are degraded by exo- and endonucleases that
recognize specific sequences or structures in their targets.
The MCPIP family of proteins are endonucleases that de-
grade mRNA transcripts by recognizing the stem-loop
structure(s) at the 3′ UTR end of mRNA. Among MCPIPs,
MCPIP1 is the best-described protein, and previous studies
have shown that this protein regulates transcripts involved
in processes such as inflammation, cell metabolism, angio-
genesis, differentiation, proliferation and apoptosis. MCPIP1
degrades pri-miRNAs in addition to mRNAs. MCPIP1 activ-
ity results in control of the intracellular level of RNA and
miRNA molecules. The exact list of transcripts is unknown
and requires detailed study based on analysis of the inter-
action of MCPIP1 proteins with the RNA pool and sequen-
cing of matrices purified after immunoprecipitation with
antibodies specific for MCPIP1. MCPIP1 can regulate the
level of transcripts directly by degrading them or indirectly
by degrading the regulators of their expression, e.g., the
mRNAs of transcription factors that regulate the expression
of these transcripts, or by degrading specific miRNAs.
Further research is necessary to explain the factors that
control the recognition of specific templates by MCPIP
family members and determine the activation of a specific
MCPIP under distinct physiological and pathological con-
ditions. Furthermore, the correlations between MCPIP1
expression and tumour types and cancer stages need fur-
ther investigation.
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